In the FIGHT study (NCT03343301), a global, randomized, double-blind, placebo-controlled phase 2 trial, patients with unresectable locally advanced or metastatic gastric/-esophageal junction carcinoma were enrolled if their tumor was HER2-negative and positive for FGFR2b overexpression by centrally performed immunohistochemistry or for FGFR2 amplification determined by circulating tumor DNA (ctDNA) (Catenacci et al. 2019). Here, ERBB2 is linked to neoplasm.